COVID19 Clinical Trial
Official title:
Let It Out (LIO) and COVID19: a Randomised Controlled Trial of an Online Emotional Disclosure-based Intervention for Adults During the COVID19 Pandemic
A randomised controlled trial designed to test whether an online expressive writing
intervention (LIO-C) can reduce distress for English-speaking adults during the global
COVID19 pandemic.
Hypothesis: LIO-C will improve distress (as measured by K10) in adults at 1 week
post-intervention compared to a neutral writing control during the COVID19 pandemic.
The world is currently experiencing unprecedented challenges caused by the global coronavirus
(COVID19) pandemic. Many countries are enforcing measures to restrict movement of people to
reduce the spread of the outbreak, including lock-downs, social distancing and
self-isolation. These methods, although necessary to slow the spread of disease, will have
negative effects on psychological well-being of large populations. Shortage of health care
professionals and measures to restrict interpersonal contact means facilitated psychological
interventions will not be feasible for many, at least during the height of the pandemic.
There is therefore a need for self-directed psychological interventions that can be
practically and quickly implemented online.
Emotional disclosure-based therapies, such as expressive writing (EW), hold potential as
low-cost, easy to implement means of support, with minimal requirement for facilitation. In
its original format, EW involved writing daily for 15-20 minutes for 3-4 days about a
traumatic event. Since its development, it has been adapted in many ways, including writing
about positive events and writing about stress from a compassionate stance. There is evidence
that such interventions can provide significant psychological and physical benefits in
healthy populations and reduce the effects of natural disasters on health and well-being.
However, to our knowledge this form of psychological intervention has not been tested during
a rapidly evolving crisis or pandemic.
The aim of this study is to test whether an online self-compassion and EW based intervention
(LIO-C) can reduce the negative effects of the COVID19 pandemic on health and well-being. The
intervention is based on an existing intervention, LIO, that we previously developed for use
in advanced disease populations, in collaboration with clinical and health psychologists, and
patient and public representatives. For this study, we have adapted the intervention for
people living through the current COVID19 pandemic by altering the writing prompts, and
translating the intervention to an online hub. As this is an unfacilitated intervention, the
instructions involve writing from a compassionate stance to minimise any potential short term
negative effects associated with writing about difficult experiences.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |